123207-48-7

Usage

Uses

Used in Pharmaceutical Industry:
3-(Morpholin-4-ylmethyl)aniline is used as a building block for the synthesis of pharmaceutical drugs due to its unique chemical structure and potential medicinal properties. It contributes to the development of new drug candidates that can address various health conditions.
Used in Chemical Industry:
In the chemical industry, 3-(Morpholin-4-ylmethyl)aniline is utilized as a reagent in organic synthesis for the preparation of a wide range of compounds. Its versatility in chemical reactions makes it valuable for creating diverse organic products.
Used in Research and Development:
3-(Morpholin-4-ylmethyl)aniline is used as a research compound for studying its potential medicinal properties and exploring its applications in drug development. This involves investigating its interactions with biological systems and assessing its efficacy and safety as a pharmaceutical agent.

InChI:InChI=1/C11H16N2O/c12-11-3-1-2-10(8-11)9-13-4-6-14-7-5-13/h1-3,8H,4-7,9,12H2

Upstream product

• 123207-57-8 3-(N-Morpholinomethyl)-1-nitrobenzene 
• 110-91-8 morpholine 
• 1709-44-0 m-aminobenzaldehyde 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 1877-77-6 3-aminobenzenemethanol 
• 99-61-6 3-nitro-benzaldehyde 

Downstream Products

• 224787-87-5 C₂₉H₃₆N₆O₅S 
• 503183-13-9 4-[(3-(morpholin-4-ylmethyl)phenyl)hydrazono]-4H-pyrazole-3,5-diamine 
• 123207-46-5 N-[3-[(4-morpholinyl)methyl]phenyl]-2-pyridinecarbothioamide 
• 936092-66-9 5-methyl-N₂-3-(3-(morpholinomethyl)phenyl)pyrimidine-2,4-diamine 
• 1174118-29-6 6-ethoxy-N-furan-2-ylmethyl-N'-(3-morpholin-4-ylmethyl-phenyl)-[1,3,5]triazine-2,4-diamine 
• 1443438-06-9 C₂₆H₂₇F₆N₃O₃ 
• 1256163-42-4 5-(3-(morpholinomethyl)phenylamino)pyrazolo[1,5-a]pyrimidine-3-carbaldehyde 
• 1142946-00-6 [4-(4-methyl-thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(3-morpholin-4-ylmethyl-phenyl)-amine 
• 1142948-06-8 C₃₂H₃₅N₅O₄S₂ 
• 1142948-04-6 C₃₀H₂₉N₅O₄S₂ 
• 1119899-58-9 5-(6-formylquinolin-4-yl)-N-(3-(morpholinomethyl)phenyl)thiophene-2-carboxamide 

Relevant academic research and scientific papers

Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity

Receptor tyrosine kinase PDGFRα is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFRα and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFRα and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFRα and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFRα signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia.

IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS)

The invention provides a compound of formula (I) (Formula (I)) or a tautomeric form, stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, wherein R2, R3, R4, Ra, Rb

BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS

The present invention is directed to 3-phenylimidazol[4,5-b]pyridine derivatives, that are selective ligands for GABAA receptors. These compounds are useful in the treatment and prevention of disorders of the central nervous system, including anxiety and convulsions.

Use of polymer supported reagents for clean multi-step organic synthesis: Preparation of amines and amine derivatives from alcohols for use in compound library generation

The automated sequential application of polymer supported perruthenate (PSP) and polymer supported cyanoborohydride (PSCBH) in an oxidation-reductive amination procedure allowed the efficient transformation of simple alcohols into more complex amines which can be further derivatised by the use of polymer bound amino sulfonylpyridinium chlorides.

N-phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: Structure-activity studies and demonstration of in vivo activity

Selective inhibition of the neuronal isoform of nitric oxide synthase (NOS) compared to the endothelial and inducible isoforms may be required for treatment of neurological disorders caused by excessive production of nitric oxide. Recently, we described N-(3-(aminomethyl)benzyl)acetamidine (13) as a slow, tight-binding inhibitor, highly selective for human inducible nitric oxide synthase (iNOS). Removal of a single methylene bridge between the amidine nitrogen and phenyl ring to give N-(3- (aminomethyl)phenyl)acetamidine (14) dramatically altered the selectivity to give a neuronal selective nitric oxide synthase (nNOS) inhibitor. Part of this large shift in selectivity was due to 14 being a rapidly reversible inhibitor of iNOS in contrast to the essentially irreversible inhibition of iNOS observed with 13. Structure-activity studies revealed that a basic amine functionality tethered to an aromatic ring and a sterically compact amidine are key pharmacophores for this class of NOS inhibitors. Maximal nNOS inhibition potency was achieved with N-(3-(aminomethyl)phenyl)-2- furanylamidine (77) (K(i-nNOS) = 0.006 μM; K(i-eNOS) = 0.35 μM; K(i-iNOS) = 0.16 μM). Finally, α-fluoro-N-(3-(aminomethyl)phenyl)acetamidine (74) (K(i- nNOS) = 0.011 μM; K(i-eNOS) = 1.1 μM; K(i-iNOS) = 0.48 μM) had excellent brain penetration and inhibited nNOS in a rat brain slice assay as well as in the rat brain (cerebellum) in vivo. Thus, N-phenylamidines should be useful in validating the role of nNOS in neurological disorders.

N-Phenyl-2-pyridinecarbothioamides as Gastric Mucosal Protectants

A series of substituted 2-pyridinecarbothioamides was synthesized and evaluated for gastric mucosal protectant activity in the rat.Out of this investigation N-(3,5-difluorophenyl)-2-pyridinecarbothioamide (23, AY-31,574) was identified.This compound was m